Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
Open Access
- 1 February 2022
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (1) , e00924
Abstract
Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies, gefapixant was eliminated primarily by renal excretion of the parent drug. The objective of this study was to assess the disposition of gefapixant in humans. The absorption, metabolism, and excretion profiles of gefapixant were assessed after oral administration of a single dose of [14C]gefapixant to six healthy adult males. Following a single‐oral [14C]gefapixant dose to healthy adult males, the mass balance was achieved, with 98.9% of the administered radioactivity recovered in urine and feces. Elimination of gefapixant occurred primarily via renal excretion of the intact drug (64%); metabolism was a minor pathway of elimination of gefapixant (12% and 2% recovered in urine and feces, respectively). Single‐dose administration of [14C]gefapixant 50 mg was generally well tolerated in healthy adult males. The fraction of the anticipated therapeutic oral dose of gefapixant absorbed is estimated to be at least 78%. Gefapixant is expected to be the major circulating drug‐related material in plasma, and the majority of the dosed drug will be excreted unchanged in urine.Keywords
Funding Information
- Merck
This publication has 13 references indexed in Scilit:
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialThe Lancet Respiratory Medicine, 2020
- Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic coughPulmonary Pharmacology & Therapeutics, 2019
- Localization of TRPV1 and P2X3 in unmyelinated and myelinated vagal afferents in the ratJournal of Chemical Neuroanatomy, 2016
- P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 studyThe Lancet, 2015
- The global epidemiology of chronic cough in adults: a systematic review and meta-analysisEuropean Respiratory Journal, 2015
- Chronic cough as a neuropathic disorderThe Lancet Respiratory Medicine, 2013
- A role for ATP in bronchoconstriction‐induced activation of guinea pig vagal intrapulmonary C‐fibresThe Journal of Physiology, 2012
- In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitizationPurinergic Signalling, 2011
- P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagusAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Determination of mean valproic acid serum level by assay of a single pooled sampleClinical Pharmacology & Therapeutics, 1981